Skip to content
Dossier Experts

Dossier Experts

Trusted Pharma Guidance

  • About UsExpand
    • Testimonials
  • Our ServicesExpand
    • Document Review
    • Dossier Preparation
    • Gap Analysis
    • Labeling and Documentation
    • Post-Approval Variations
    • Quality Assurance
    • Regulatory Strategy
    • Risk Assessment
  • ResourcesExpand
    • Regulatory Intelligence
  • InsightsExpand
    • News & Updates
    • The Knowledge ShelfExpand
      • MHRA Updates
      • US FDA News
  • RA TrainingExpand
    • Regulatory Training
    • Glossary of Terms
  • Contact UsExpand
    • Privacy Policy
    • Terms and Conditions
    • Client Portal
    • Careers
Get Started
Dossier Experts
Dossier Experts
Trusted Pharma Guidance
MHRA

Access, new active substance and biosimilar work sharing initiatives

ByDossier Experts June 6, 2025

Information on applying for New Active Substance Work Sharing Initiative (NASWSI) and Biosimilar Work Sharing Initiative (BSWSI) assessments and list of approved products.

Share this:

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X

Related

Post navigation

Previous Previous
Serious liver injury being observed in patients without cirrhosis taking Ocaliva (obeticholic acid) to treat primary biliary cholangitis
NextContinue
2023 Meeting Materials, Cardiovascular and Renal Drugs Advisory Committee
What happens next?
Once you submit this form, our team will review your message and respond within 1–2 working days. You’ll receive a confirmation email shortly after submission.

Data Protection Notice:
We respect your privacy and follow strict GDPR guidelines. Your information will only be used to respond to your enquiry and will not be shared with third parties. You can request to have your data removed at any time.
Dossier Experts

We offer tailored services to meet our clients' needs, focusing on high-quality results and lasting partnerships.

Quick Links

  • Home
  • About Us
  • Services
  • Contact
  • Blog

Our Services

  • Regulatory Submissions
  • Product Registration
  • Labeling & Documentation
  • Risk Assessment
  • Regulatory Strategy

Legal & Info

  • Privacy Policy
  • Terms & Conditions
  • Cookie Policy
  • FAQ
  • Sitemap

Contact

Email: hi@dossierexperts.com RA@: regs@dossierexperts.com

Phone: +44 07448372840

© 2025 Dossier Experts - WordPress Theme by Kadence WP

  • About Us
  • Our Services
  • Resources
  • Insights
  • RA Training
  • Contact Us
Scroll to top
  • About Us
    • Testimonials
  • Our Services
    • Document Review
    • Dossier Preparation
    • Gap Analysis
    • Labeling and Documentation
    • Post-Approval Variations
    • Quality Assurance
    • Regulatory Strategy
    • Risk Assessment
  • Resources
    • Regulatory Intelligence
  • Insights
    • News & Updates
    • The Knowledge Shelf
      • MHRA Updates
      • US FDA News
  • RA Training
    • Regulatory Training
    • Glossary of Terms
  • Contact Us
    • Privacy Policy
    • Terms and Conditions
    • Client Portal
    • Careers